# AbbVie quarterly revenue

entity: /record/abbvie.md  
predicate: quarterly_revenue  
page: /record/abbvie/quarterly_revenue  
as_of: 2026-11-09  
cite: AsOf. "AbbVie quarterly revenue: 17,404,000,000 United States dollar", as of 2026-09-30. Claim clm_DA52AAE1BFB4, https://asof.is/claim/clm_DA52AAE1BFB4, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115226000037/0001551152-26-000037-index.htm.  

As of November 9, 2026, AbbVie's quarterly revenue on the AsOf record is $17.4 billion, dated September 30, 2026, from a primary source (sec.gov).

45 claims on AbbVie's quarterly revenue, 1 open and 44 superseded, each dated and sourced; a replaced value is closed with an end date, never deleted.

## Current quarterly revenue

What the record asserts on 2026-11-09.

- [AbbVie](/record/abbvie.md) | quarterly_revenue | 17,404,000,000 United States dollar | valid 2026-09-30 to present | conf 0.95 | valid | [clm_DA52AAE1BFB4](/claim/clm_DA52AAE1BFB4.md)
  sources: https://www.sec.gov/Archives/edgar/data/1551152/000155115226000037/0001551152-26-000037-index.htm

## Every dated value

One claim per line, oldest first. Superseded claims stay visible.

- [AbbVie](/record/abbvie.md) | quarterly_revenue | 4,173,000,000 United States dollar | valid 2012-03-31 to 2012-06-30 | conf 0.95 | superseded | superseded_by [clm_FEDE06BBE100](/claim/clm_FEDE06BBE100.md) | [clm_F93636EB7531](/claim/clm_F93636EB7531.md)
  sources: https://www.sec.gov/Archives/edgar/data/1551152/000110465913038917/0001104659-13-038917-index.htm
- [AbbVie](/record/abbvie.md) | quarterly_revenue | 4,493,000,000 United States dollar | valid 2012-06-30 to 2012-09-30 | conf 0.95 | superseded | superseded_by [clm_B5C99B331875](/claim/clm_B5C99B331875.md) | [clm_FEDE06BBE100](/claim/clm_FEDE06BBE100.md)
  sources: https://www.sec.gov/Archives/edgar/data/1551152/000110465913062262/0001104659-13-062262-index.htm
- [AbbVie](/record/abbvie.md) | quarterly_revenue | 4,508,000,000 United States dollar | valid 2012-09-30 to 2013-03-31 | conf 0.95 | superseded | superseded_by [clm_8FCC99AEFBF3](/claim/clm_8FCC99AEFBF3.md) | [clm_B5C99B331875](/claim/clm_B5C99B331875.md)
  sources: https://www.sec.gov/Archives/edgar/data/1551152/000110465913083686/0001104659-13-083686-index.htm
- [AbbVie](/record/abbvie.md) | quarterly_revenue | 4,329,000,000 United States dollar | valid 2013-03-31 to 2013-06-30 | conf 0.95 | superseded | superseded_by [clm_9BDF5524D4D8](/claim/clm_9BDF5524D4D8.md) | [clm_8FCC99AEFBF3](/claim/clm_8FCC99AEFBF3.md)
  sources: https://www.sec.gov/Archives/edgar/data/1551152/000110465913038917/0001104659-13-038917-index.htm
- [AbbVie](/record/abbvie.md) | quarterly_revenue | 4,692,000,000 United States dollar | valid 2013-06-30 to 2013-09-30 | conf 0.95 | superseded | superseded_by [clm_A061D1ED53C1](/claim/clm_A061D1ED53C1.md) | [clm_9BDF5524D4D8](/claim/clm_9BDF5524D4D8.md)
  sources: https://www.sec.gov/Archives/edgar/data/1551152/000110465913062262/0001104659-13-062262-index.htm
- [AbbVie](/record/abbvie.md) | quarterly_revenue | 4,658,000,000 United States dollar | valid 2013-09-30 to 2014-03-31 | conf 0.95 | superseded | superseded_by [clm_3B799E473A52](/claim/clm_3B799E473A52.md) | [clm_A061D1ED53C1](/claim/clm_A061D1ED53C1.md)
  sources: https://www.sec.gov/Archives/edgar/data/1551152/000110465913083686/0001104659-13-083686-index.htm
- [AbbVie](/record/abbvie.md) | quarterly_revenue | 4,563,000,000 United States dollar | valid 2014-03-31 to 2014-06-30 | conf 0.95 | superseded | superseded_by [clm_DA4F15CF335B](/claim/clm_DA4F15CF335B.md) | [clm_3B799E473A52](/claim/clm_3B799E473A52.md)
  sources: https://www.sec.gov/Archives/edgar/data/1551152/000110465914036968/0001104659-14-036968-index.htm
- [AbbVie](/record/abbvie.md) | quarterly_revenue | 4,926,000,000 United States dollar | valid 2014-06-30 to 2014-09-30 | conf 0.95 | superseded | superseded_by [clm_A7029DF5DA96](/claim/clm_A7029DF5DA96.md) | [clm_DA4F15CF335B](/claim/clm_DA4F15CF335B.md)
  sources: https://www.sec.gov/Archives/edgar/data/1551152/000110465915057641/0001104659-15-057641-index.htm
- [AbbVie](/record/abbvie.md) | quarterly_revenue | 5,019,000,000 United States dollar | valid 2014-09-30 to 2015-03-31 | conf 0.95 | superseded | superseded_by [clm_EEF0B5482085](/claim/clm_EEF0B5482085.md) | [clm_A7029DF5DA96](/claim/clm_A7029DF5DA96.md)
  sources: https://www.sec.gov/Archives/edgar/data/1551152/000110465915076607/0001104659-15-076607-index.htm
- [AbbVie](/record/abbvie.md) | quarterly_revenue | 5,040,000,000 United States dollar | valid 2015-03-31 to 2015-06-30 | conf 0.95 | superseded | superseded_by [clm_C287D4F05535](/claim/clm_C287D4F05535.md) | [clm_EEF0B5482085](/claim/clm_EEF0B5482085.md)
  sources: https://www.sec.gov/Archives/edgar/data/1551152/000110465916118639/0001104659-16-118639-index.htm
- [AbbVie](/record/abbvie.md) | quarterly_revenue | 5,475,000,000 United States dollar | valid 2015-06-30 to 2015-09-30 | conf 0.95 | superseded | superseded_by [clm_9DB567EABED1](/claim/clm_9DB567EABED1.md) | [clm_C287D4F05535](/claim/clm_C287D4F05535.md)
  sources: https://www.sec.gov/Archives/edgar/data/1551152/000110465915057641/0001104659-15-057641-index.htm
- [AbbVie](/record/abbvie.md) | quarterly_revenue | 5,944,000,000 United States dollar | valid 2015-09-30 to 2016-03-31 | conf 0.95 | superseded | superseded_by [clm_50CDB8FC3EC3](/claim/clm_50CDB8FC3EC3.md) | [clm_9DB567EABED1](/claim/clm_9DB567EABED1.md)
  sources: https://www.sec.gov/Archives/edgar/data/1551152/000110465915076607/0001104659-15-076607-index.htm
- [AbbVie](/record/abbvie.md) | quarterly_revenue | 5,958,000,000 United States dollar | valid 2016-03-31 to 2016-06-30 | conf 0.95 | superseded | superseded_by [clm_E445263E135D](/claim/clm_E445263E135D.md) | [clm_50CDB8FC3EC3](/claim/clm_50CDB8FC3EC3.md)
  sources: https://www.sec.gov/Archives/edgar/data/1551152/000110465916118639/0001104659-16-118639-index.htm
- [AbbVie](/record/abbvie.md) | quarterly_revenue | 6,452,000,000 United States dollar | valid 2016-06-30 to 2016-09-30 | conf 0.95 | superseded | superseded_by [clm_2A4B013AE0D7](/claim/clm_2A4B013AE0D7.md) | [clm_E445263E135D](/claim/clm_E445263E135D.md)
  sources: https://www.sec.gov/Archives/edgar/data/1551152/000110465916137453/0001104659-16-137453-index.htm
- [AbbVie](/record/abbvie.md) | quarterly_revenue | 6,432,000,000 United States dollar | valid 2016-09-30 to 2017-03-31 | conf 0.95 | superseded | superseded_by [clm_91E1E8F4CFBF](/claim/clm_91E1E8F4CFBF.md) | [clm_2A4B013AE0D7](/claim/clm_2A4B013AE0D7.md)
  sources: https://www.sec.gov/Archives/edgar/data/1551152/000155115216000005/0001551152-16-000005-index.htm
- [AbbVie](/record/abbvie.md) | quarterly_revenue | 6,538,000,000 United States dollar | valid 2017-03-31 to 2017-06-30 | conf 0.95 | superseded | superseded_by [clm_57888AB73869](/claim/clm_57888AB73869.md) | [clm_91E1E8F4CFBF](/claim/clm_91E1E8F4CFBF.md)
  sources: https://www.sec.gov/Archives/edgar/data/1551152/000155115217000016/0001551152-17-000016-index.htm
- [AbbVie](/record/abbvie.md) | quarterly_revenue | 6,944,000,000 United States dollar | valid 2017-06-30 to 2017-09-30 | conf 0.95 | superseded | superseded_by [clm_6578B80CE1C3](/claim/clm_6578B80CE1C3.md) | [clm_57888AB73869](/claim/clm_57888AB73869.md)
  sources: https://www.sec.gov/Archives/edgar/data/1551152/000155115217000025/0001551152-17-000025-index.htm
- [AbbVie](/record/abbvie.md) | quarterly_revenue | 6,995,000,000 United States dollar | valid 2017-09-30 to 2018-03-31 | conf 0.95 | superseded | superseded_by [clm_638ECD9CFFA0](/claim/clm_638ECD9CFFA0.md) | [clm_6578B80CE1C3](/claim/clm_6578B80CE1C3.md)
  sources: https://www.sec.gov/Archives/edgar/data/1551152/000155115217000035/0001551152-17-000035-index.htm
- [AbbVie](/record/abbvie.md) | quarterly_revenue | 7,934,000,000 United States dollar | valid 2018-03-31 to 2018-06-30 | conf 0.95 | superseded | superseded_by [clm_BDC07E3C1093](/claim/clm_BDC07E3C1093.md) | [clm_638ECD9CFFA0](/claim/clm_638ECD9CFFA0.md)
  sources: https://www.sec.gov/Archives/edgar/data/1551152/000155115218000025/0001551152-18-000025-index.htm
- [AbbVie](/record/abbvie.md) | quarterly_revenue | 8,278,000,000 United States dollar | valid 2018-06-30 to 2018-09-30 | conf 0.95 | superseded | superseded_by [clm_EF6AEA6051C0](/claim/clm_EF6AEA6051C0.md) | [clm_BDC07E3C1093](/claim/clm_BDC07E3C1093.md)
  sources: https://www.sec.gov/Archives/edgar/data/1551152/000155115218000032/0001551152-18-000032-index.htm
- [AbbVie](/record/abbvie.md) | quarterly_revenue | 8,236,000,000 United States dollar | valid 2018-09-30 to 2019-03-31 | conf 0.95 | superseded | superseded_by [clm_7B8BB25C6DC4](/claim/clm_7B8BB25C6DC4.md) | [clm_EF6AEA6051C0](/claim/clm_EF6AEA6051C0.md)
  sources: https://www.sec.gov/Archives/edgar/data/1551152/000155115218000042/0001551152-18-000042-index.htm
- [AbbVie](/record/abbvie.md) | quarterly_revenue | 7,828,000,000 United States dollar | valid 2019-03-31 to 2019-06-30 | conf 0.95 | superseded | superseded_by [clm_13C8A0924EB0](/claim/clm_13C8A0924EB0.md) | [clm_7B8BB25C6DC4](/claim/clm_7B8BB25C6DC4.md)
  sources: https://www.sec.gov/Archives/edgar/data/1551152/000155115219000016/0001551152-19-000016-index.htm
- [AbbVie](/record/abbvie.md) | quarterly_revenue | 8,255,000,000 United States dollar | valid 2019-06-30 to 2019-09-30 | conf 0.95 | superseded | superseded_by [clm_CB0B88225C13](/claim/clm_CB0B88225C13.md) | [clm_13C8A0924EB0](/claim/clm_13C8A0924EB0.md)
  sources: https://www.sec.gov/Archives/edgar/data/1551152/000155115219000023/0001551152-19-000023-index.htm
- [AbbVie](/record/abbvie.md) | quarterly_revenue | 8,479,000,000 United States dollar | valid 2019-09-30 to 2020-03-31 | conf 0.95 | superseded | superseded_by [clm_A47008E5C136](/claim/clm_A47008E5C136.md) | [clm_CB0B88225C13](/claim/clm_CB0B88225C13.md)
  sources: https://www.sec.gov/Archives/edgar/data/1551152/000155115219000030/0001551152-19-000030-index.htm
- [AbbVie](/record/abbvie.md) | quarterly_revenue | 8,619,000,000 United States dollar | valid 2020-03-31 to 2020-06-30 | conf 0.95 | superseded | superseded_by [clm_1FA32CF37088](/claim/clm_1FA32CF37088.md) | [clm_A47008E5C136](/claim/clm_A47008E5C136.md)
  sources: https://www.sec.gov/Archives/edgar/data/1551152/000155115220000015/0001551152-20-000015-index.htm
- [AbbVie](/record/abbvie.md) | quarterly_revenue | 10,425,000,000 United States dollar | valid 2020-06-30 to 2020-09-30 | conf 0.95 | superseded | superseded_by [clm_91BA7A736154](/claim/clm_91BA7A736154.md) | [clm_1FA32CF37088](/claim/clm_1FA32CF37088.md)
  sources: https://www.sec.gov/Archives/edgar/data/1551152/000155115220000023/0001551152-20-000023-index.htm
- [AbbVie](/record/abbvie.md) | quarterly_revenue | 12,902,000,000 United States dollar | valid 2020-09-30 to 2021-03-31 | conf 0.95 | superseded | superseded_by [clm_0285E2C1A7E7](/claim/clm_0285E2C1A7E7.md) | [clm_91BA7A736154](/claim/clm_91BA7A736154.md)
  sources: https://www.sec.gov/Archives/edgar/data/1551152/000155115220000032/0001551152-20-000032-index.htm
- [AbbVie](/record/abbvie.md) | quarterly_revenue | 13,010,000,000 United States dollar | valid 2021-03-31 to 2021-06-30 | conf 0.95 | superseded | superseded_by [clm_5F5081E18D14](/claim/clm_5F5081E18D14.md) | [clm_0285E2C1A7E7](/claim/clm_0285E2C1A7E7.md)
  sources: https://www.sec.gov/Archives/edgar/data/1551152/000155115221000016/0001551152-21-000016-index.htm
- [AbbVie](/record/abbvie.md) | quarterly_revenue | 13,959,000,000 United States dollar | valid 2021-06-30 to 2021-09-30 | conf 0.95 | superseded | superseded_by [clm_7EFD9B1EE312](/claim/clm_7EFD9B1EE312.md) | [clm_5F5081E18D14](/claim/clm_5F5081E18D14.md)
  sources: https://www.sec.gov/Archives/edgar/data/1551152/000155115221000025/0001551152-21-000025-index.htm
- [AbbVie](/record/abbvie.md) | quarterly_revenue | 14,342,000,000 United States dollar | valid 2021-09-30 to 2022-03-31 | conf 0.95 | superseded | superseded_by [clm_020CA528788D](/claim/clm_020CA528788D.md) | [clm_7EFD9B1EE312](/claim/clm_7EFD9B1EE312.md)
  sources: https://www.sec.gov/Archives/edgar/data/1551152/000155115221000031/0001551152-21-000031-index.htm
- [AbbVie](/record/abbvie.md) | quarterly_revenue | 13,538,000,000 United States dollar | valid 2022-03-31 to 2022-06-30 | conf 0.95 | superseded | superseded_by [clm_FC05FDDBEA11](/claim/clm_FC05FDDBEA11.md) | [clm_020CA528788D](/claim/clm_020CA528788D.md)
  sources: https://www.sec.gov/Archives/edgar/data/1551152/000155115222000017/0001551152-22-000017-index.htm
- [AbbVie](/record/abbvie.md) | quarterly_revenue | 14,583,000,000 United States dollar | valid 2022-06-30 to 2022-09-30 | conf 0.95 | superseded | superseded_by [clm_180AA5A76ED5](/claim/clm_180AA5A76ED5.md) | [clm_FC05FDDBEA11](/claim/clm_FC05FDDBEA11.md)
  sources: https://www.sec.gov/Archives/edgar/data/1551152/000155115222000030/0001551152-22-000030-index.htm
- [AbbVie](/record/abbvie.md) | quarterly_revenue | 14,812,000,000 United States dollar | valid 2022-09-30 to 2023-03-31 | conf 0.95 | superseded | superseded_by [clm_CBFCA4B48C56](/claim/clm_CBFCA4B48C56.md) | [clm_180AA5A76ED5](/claim/clm_180AA5A76ED5.md)
  sources: https://www.sec.gov/Archives/edgar/data/1551152/000155115222000045/0001551152-22-000045-index.htm
- [AbbVie](/record/abbvie.md) | quarterly_revenue | 12,225,000,000 United States dollar | valid 2023-03-31 to 2023-06-30 | conf 0.95 | superseded | superseded_by [clm_593BEB422FF1](/claim/clm_593BEB422FF1.md) | [clm_CBFCA4B48C56](/claim/clm_CBFCA4B48C56.md)
  sources: https://www.sec.gov/Archives/edgar/data/1551152/000155115223000023/0001551152-23-000023-index.htm
- [AbbVie](/record/abbvie.md) | quarterly_revenue | 13,865,000,000 United States dollar | valid 2023-06-30 to 2023-09-30 | conf 0.95 | superseded | superseded_by [clm_2E4438989255](/claim/clm_2E4438989255.md) | [clm_593BEB422FF1](/claim/clm_593BEB422FF1.md)
  sources: https://www.sec.gov/Archives/edgar/data/1551152/000155115223000033/0001551152-23-000033-index.htm
- [AbbVie](/record/abbvie.md) | quarterly_revenue | 13,927,000,000 United States dollar | valid 2023-09-30 to 2024-03-31 | conf 0.95 | superseded | superseded_by [clm_E449A119B758](/claim/clm_E449A119B758.md) | [clm_2E4438989255](/claim/clm_2E4438989255.md)
  sources: https://www.sec.gov/Archives/edgar/data/1551152/000155115223000045/0001551152-23-000045-index.htm
- [AbbVie](/record/abbvie.md) | quarterly_revenue | 12,310,000,000 United States dollar | valid 2024-03-31 to 2024-06-30 | conf 0.95 | superseded | superseded_by [clm_702A9C257ED5](/claim/clm_702A9C257ED5.md) | [clm_E449A119B758](/claim/clm_E449A119B758.md)
  sources: https://www.sec.gov/Archives/edgar/data/1551152/000155115224000020/0001551152-24-000020-index.htm
- [AbbVie](/record/abbvie.md) | quarterly_revenue | 14,462,000,000 United States dollar | valid 2024-06-30 to 2024-09-30 | conf 0.95 | superseded | superseded_by [clm_1DE14AF1FBB3](/claim/clm_1DE14AF1FBB3.md) | [clm_702A9C257ED5](/claim/clm_702A9C257ED5.md)
  sources: https://www.sec.gov/Archives/edgar/data/1551152/000155115224000031/0001551152-24-000031-index.htm
- [AbbVie](/record/abbvie.md) | quarterly_revenue | 14,460,000,000 United States dollar | valid 2024-09-30 to 2025-03-31 | conf 0.95 | superseded | superseded_by [clm_8213D3858DF4](/claim/clm_8213D3858DF4.md) | [clm_1DE14AF1FBB3](/claim/clm_1DE14AF1FBB3.md)
  sources: https://www.sec.gov/Archives/edgar/data/1551152/000155115224000040/0001551152-24-000040-index.htm
- [AbbVie](/record/abbvie.md) | quarterly_revenue | 13,343,000,000 United States dollar | valid 2025-03-31 to 2025-06-30 | conf 0.95 | superseded | superseded_by [clm_83F895DA4455](/claim/clm_83F895DA4455.md) | [clm_8213D3858DF4](/claim/clm_8213D3858DF4.md)
  sources: https://www.sec.gov/Archives/edgar/data/1551152/000155115225000029/0001551152-25-000029-index.htm
- [AbbVie](/record/abbvie.md) | quarterly_revenue | 15,423,000,000 United States dollar | valid 2025-06-30 to 2025-09-30 | conf 0.95 | superseded | superseded_by [clm_7673BF825A9D](/claim/clm_7673BF825A9D.md) | [clm_83F895DA4455](/claim/clm_83F895DA4455.md)
  sources: https://www.sec.gov/Archives/edgar/data/1551152/000155115225000040/0001551152-25-000040-index.htm
- [AbbVie](/record/abbvie.md) | quarterly_revenue | 15,776,000,000 United States dollar | valid 2025-09-30 to 2026-03-31 | conf 0.95 | superseded | superseded_by [clm_2A1D46B6132E](/claim/clm_2A1D46B6132E.md) | [clm_7673BF825A9D](/claim/clm_7673BF825A9D.md)
  sources: https://www.sec.gov/Archives/edgar/data/1551152/000155115225000049/0001551152-25-000049-index.htm
- [AbbVie](/record/abbvie.md) | quarterly_revenue | 15,002,000,000 United States dollar | valid 2026-03-31 to 2026-06-30 | conf 0.95 | superseded | superseded_by [clm_E6270C8DB4ED](/claim/clm_E6270C8DB4ED.md) | [clm_2A1D46B6132E](/claim/clm_2A1D46B6132E.md)
  sources: https://www.sec.gov/Archives/edgar/data/1551152/000155115226000017/0001551152-26-000017-index.htm
- [AbbVie](/record/abbvie.md) | quarterly_revenue | 16,990,000,000 United States dollar | valid 2026-06-30 to 2026-09-30 | conf 0.95 | superseded | superseded_by [clm_DA52AAE1BFB4](/claim/clm_DA52AAE1BFB4.md) | [clm_E6270C8DB4ED](/claim/clm_E6270C8DB4ED.md)
  sources: https://www.sec.gov/Archives/edgar/data/1551152/000155115226000026/0001551152-26-000026-index.htm
- [AbbVie](/record/abbvie.md) | quarterly_revenue | 17,404,000,000 United States dollar | valid 2026-09-30 to present | conf 0.95 | valid | [clm_DA52AAE1BFB4](/claim/clm_DA52AAE1BFB4.md)
  sources: https://www.sec.gov/Archives/edgar/data/1551152/000155115226000037/0001551152-26-000037-index.htm

## What replaced what

- $4.17 billion (2012-03-31 to 2012-06-30, [clm_F93636EB7531](/claim/clm_F93636EB7531.md)) was replaced by $4.49 billion from 2012-06-30 ([clm_FEDE06BBE100](/claim/clm_FEDE06BBE100.md))
- $4.49 billion (2012-06-30 to 2012-09-30, [clm_FEDE06BBE100](/claim/clm_FEDE06BBE100.md)) was replaced by $4.51 billion from 2012-09-30 ([clm_B5C99B331875](/claim/clm_B5C99B331875.md))
- $4.51 billion (2012-09-30 to 2013-03-31, [clm_B5C99B331875](/claim/clm_B5C99B331875.md)) was replaced by $4.33 billion from 2013-03-31 ([clm_8FCC99AEFBF3](/claim/clm_8FCC99AEFBF3.md))
- $4.33 billion (2013-03-31 to 2013-06-30, [clm_8FCC99AEFBF3](/claim/clm_8FCC99AEFBF3.md)) was replaced by $4.69 billion from 2013-06-30 ([clm_9BDF5524D4D8](/claim/clm_9BDF5524D4D8.md))
- $4.69 billion (2013-06-30 to 2013-09-30, [clm_9BDF5524D4D8](/claim/clm_9BDF5524D4D8.md)) was replaced by $4.66 billion from 2013-09-30 ([clm_A061D1ED53C1](/claim/clm_A061D1ED53C1.md))
- $4.66 billion (2013-09-30 to 2014-03-31, [clm_A061D1ED53C1](/claim/clm_A061D1ED53C1.md)) was replaced by $4.56 billion from 2014-03-31 ([clm_3B799E473A52](/claim/clm_3B799E473A52.md))
- $4.56 billion (2014-03-31 to 2014-06-30, [clm_3B799E473A52](/claim/clm_3B799E473A52.md)) was replaced by $4.93 billion from 2014-06-30 ([clm_DA4F15CF335B](/claim/clm_DA4F15CF335B.md))
- $4.93 billion (2014-06-30 to 2014-09-30, [clm_DA4F15CF335B](/claim/clm_DA4F15CF335B.md)) was replaced by $5.02 billion from 2014-09-30 ([clm_A7029DF5DA96](/claim/clm_A7029DF5DA96.md))
- $5.02 billion (2014-09-30 to 2015-03-31, [clm_A7029DF5DA96](/claim/clm_A7029DF5DA96.md)) was replaced by $5.04 billion from 2015-03-31 ([clm_EEF0B5482085](/claim/clm_EEF0B5482085.md))
- $5.04 billion (2015-03-31 to 2015-06-30, [clm_EEF0B5482085](/claim/clm_EEF0B5482085.md)) was replaced by $5.48 billion from 2015-06-30 ([clm_C287D4F05535](/claim/clm_C287D4F05535.md))
- $5.48 billion (2015-06-30 to 2015-09-30, [clm_C287D4F05535](/claim/clm_C287D4F05535.md)) was replaced by $5.94 billion from 2015-09-30 ([clm_9DB567EABED1](/claim/clm_9DB567EABED1.md))
- $5.94 billion (2015-09-30 to 2016-03-31, [clm_9DB567EABED1](/claim/clm_9DB567EABED1.md)) was replaced by $5.96 billion from 2016-03-31 ([clm_50CDB8FC3EC3](/claim/clm_50CDB8FC3EC3.md))
- $5.96 billion (2016-03-31 to 2016-06-30, [clm_50CDB8FC3EC3](/claim/clm_50CDB8FC3EC3.md)) was replaced by $6.45 billion from 2016-06-30 ([clm_E445263E135D](/claim/clm_E445263E135D.md))
- $6.45 billion (2016-06-30 to 2016-09-30, [clm_E445263E135D](/claim/clm_E445263E135D.md)) was replaced by $6.43 billion from 2016-09-30 ([clm_2A4B013AE0D7](/claim/clm_2A4B013AE0D7.md))
- $6.43 billion (2016-09-30 to 2017-03-31, [clm_2A4B013AE0D7](/claim/clm_2A4B013AE0D7.md)) was replaced by $6.54 billion from 2017-03-31 ([clm_91E1E8F4CFBF](/claim/clm_91E1E8F4CFBF.md))
- $6.54 billion (2017-03-31 to 2017-06-30, [clm_91E1E8F4CFBF](/claim/clm_91E1E8F4CFBF.md)) was replaced by $6.94 billion from 2017-06-30 ([clm_57888AB73869](/claim/clm_57888AB73869.md))
- $6.94 billion (2017-06-30 to 2017-09-30, [clm_57888AB73869](/claim/clm_57888AB73869.md)) was replaced by $7 billion from 2017-09-30 ([clm_6578B80CE1C3](/claim/clm_6578B80CE1C3.md))
- $7 billion (2017-09-30 to 2018-03-31, [clm_6578B80CE1C3](/claim/clm_6578B80CE1C3.md)) was replaced by $7.93 billion from 2018-03-31 ([clm_638ECD9CFFA0](/claim/clm_638ECD9CFFA0.md))
- $7.93 billion (2018-03-31 to 2018-06-30, [clm_638ECD9CFFA0](/claim/clm_638ECD9CFFA0.md)) was replaced by $8.28 billion from 2018-06-30 ([clm_BDC07E3C1093](/claim/clm_BDC07E3C1093.md))
- $8.28 billion (2018-06-30 to 2018-09-30, [clm_BDC07E3C1093](/claim/clm_BDC07E3C1093.md)) was replaced by $8.24 billion from 2018-09-30 ([clm_EF6AEA6051C0](/claim/clm_EF6AEA6051C0.md))
- $8.24 billion (2018-09-30 to 2019-03-31, [clm_EF6AEA6051C0](/claim/clm_EF6AEA6051C0.md)) was replaced by $7.83 billion from 2019-03-31 ([clm_7B8BB25C6DC4](/claim/clm_7B8BB25C6DC4.md))
- $7.83 billion (2019-03-31 to 2019-06-30, [clm_7B8BB25C6DC4](/claim/clm_7B8BB25C6DC4.md)) was replaced by $8.26 billion from 2019-06-30 ([clm_13C8A0924EB0](/claim/clm_13C8A0924EB0.md))
- $8.26 billion (2019-06-30 to 2019-09-30, [clm_13C8A0924EB0](/claim/clm_13C8A0924EB0.md)) was replaced by $8.48 billion from 2019-09-30 ([clm_CB0B88225C13](/claim/clm_CB0B88225C13.md))
- $8.48 billion (2019-09-30 to 2020-03-31, [clm_CB0B88225C13](/claim/clm_CB0B88225C13.md)) was replaced by $8.62 billion from 2020-03-31 ([clm_A47008E5C136](/claim/clm_A47008E5C136.md))
- $8.62 billion (2020-03-31 to 2020-06-30, [clm_A47008E5C136](/claim/clm_A47008E5C136.md)) was replaced by $10.43 billion from 2020-06-30 ([clm_1FA32CF37088](/claim/clm_1FA32CF37088.md))
- $10.43 billion (2020-06-30 to 2020-09-30, [clm_1FA32CF37088](/claim/clm_1FA32CF37088.md)) was replaced by $12.9 billion from 2020-09-30 ([clm_91BA7A736154](/claim/clm_91BA7A736154.md))
- $12.9 billion (2020-09-30 to 2021-03-31, [clm_91BA7A736154](/claim/clm_91BA7A736154.md)) was replaced by $13.01 billion from 2021-03-31 ([clm_0285E2C1A7E7](/claim/clm_0285E2C1A7E7.md))
- $13.01 billion (2021-03-31 to 2021-06-30, [clm_0285E2C1A7E7](/claim/clm_0285E2C1A7E7.md)) was replaced by $13.96 billion from 2021-06-30 ([clm_5F5081E18D14](/claim/clm_5F5081E18D14.md))
- $13.96 billion (2021-06-30 to 2021-09-30, [clm_5F5081E18D14](/claim/clm_5F5081E18D14.md)) was replaced by $14.34 billion from 2021-09-30 ([clm_7EFD9B1EE312](/claim/clm_7EFD9B1EE312.md))
- $14.34 billion (2021-09-30 to 2022-03-31, [clm_7EFD9B1EE312](/claim/clm_7EFD9B1EE312.md)) was replaced by $13.54 billion from 2022-03-31 ([clm_020CA528788D](/claim/clm_020CA528788D.md))
- $13.54 billion (2022-03-31 to 2022-06-30, [clm_020CA528788D](/claim/clm_020CA528788D.md)) was replaced by $14.58 billion from 2022-06-30 ([clm_FC05FDDBEA11](/claim/clm_FC05FDDBEA11.md))
- $14.58 billion (2022-06-30 to 2022-09-30, [clm_FC05FDDBEA11](/claim/clm_FC05FDDBEA11.md)) was replaced by $14.81 billion from 2022-09-30 ([clm_180AA5A76ED5](/claim/clm_180AA5A76ED5.md))
- $14.81 billion (2022-09-30 to 2023-03-31, [clm_180AA5A76ED5](/claim/clm_180AA5A76ED5.md)) was replaced by $12.23 billion from 2023-03-31 ([clm_CBFCA4B48C56](/claim/clm_CBFCA4B48C56.md))
- $12.23 billion (2023-03-31 to 2023-06-30, [clm_CBFCA4B48C56](/claim/clm_CBFCA4B48C56.md)) was replaced by $13.87 billion from 2023-06-30 ([clm_593BEB422FF1](/claim/clm_593BEB422FF1.md))
- $13.87 billion (2023-06-30 to 2023-09-30, [clm_593BEB422FF1](/claim/clm_593BEB422FF1.md)) was replaced by $13.93 billion from 2023-09-30 ([clm_2E4438989255](/claim/clm_2E4438989255.md))
- $13.93 billion (2023-09-30 to 2024-03-31, [clm_2E4438989255](/claim/clm_2E4438989255.md)) was replaced by $12.31 billion from 2024-03-31 ([clm_E449A119B758](/claim/clm_E449A119B758.md))
- $12.31 billion (2024-03-31 to 2024-06-30, [clm_E449A119B758](/claim/clm_E449A119B758.md)) was replaced by $14.46 billion from 2024-06-30 ([clm_702A9C257ED5](/claim/clm_702A9C257ED5.md))
- $14.46 billion (2024-06-30 to 2024-09-30, [clm_702A9C257ED5](/claim/clm_702A9C257ED5.md)) was replaced by $14.46 billion from 2024-09-30 ([clm_1DE14AF1FBB3](/claim/clm_1DE14AF1FBB3.md))
- $14.46 billion (2024-09-30 to 2025-03-31, [clm_1DE14AF1FBB3](/claim/clm_1DE14AF1FBB3.md)) was replaced by $13.34 billion from 2025-03-31 ([clm_8213D3858DF4](/claim/clm_8213D3858DF4.md))
- $13.34 billion (2025-03-31 to 2025-06-30, [clm_8213D3858DF4](/claim/clm_8213D3858DF4.md)) was replaced by $15.42 billion from 2025-06-30 ([clm_83F895DA4455](/claim/clm_83F895DA4455.md))
- $15.42 billion (2025-06-30 to 2025-09-30, [clm_83F895DA4455](/claim/clm_83F895DA4455.md)) was replaced by $15.78 billion from 2025-09-30 ([clm_7673BF825A9D](/claim/clm_7673BF825A9D.md))
- $15.78 billion (2025-09-30 to 2026-03-31, [clm_7673BF825A9D](/claim/clm_7673BF825A9D.md)) was replaced by $15 billion from 2026-03-31 ([clm_2A1D46B6132E](/claim/clm_2A1D46B6132E.md))
- $15 billion (2026-03-31 to 2026-06-30, [clm_2A1D46B6132E](/claim/clm_2A1D46B6132E.md)) was replaced by $16.99 billion from 2026-06-30 ([clm_E6270C8DB4ED](/claim/clm_E6270C8DB4ED.md))
- $16.99 billion (2026-06-30 to 2026-09-30, [clm_E6270C8DB4ED](/claim/clm_E6270C8DB4ED.md)) was replaced by $17.4 billion from 2026-09-30 ([clm_DA52AAE1BFB4](/claim/clm_DA52AAE1BFB4.md))

## Questions this record answers

### What is AbbVie's current quarterly revenue?

$17.4 billion, dated September 30, 2026, from a primary source (sec.gov). The record asserts this claim as of November 9, 2026 (status valid, confidence 0.95).

### When did AbbVie's quarterly revenue last change?

The latest value on the record is $17.4 billion, dated September 30, 2026; before it the record holds $16.99 billion, dated June 30, 2026 and closed on September 30, 2026.

### What was AbbVie's quarterly revenue before $17.4 billion?

$16.99 billion, valid from June 30, 2026 to September 30, 2026 (status superseded), from a primary source (sec.gov).


## Read on

- This page: /record/abbvie/quarterly_revenue (markdown: /record/abbvie/quarterly_revenue.md)
- Entity twin: /record/abbvie.md · timeline: /timelines/abbvie.md
- Every company's quarterly revenue: /facts/quarterly_revenue.md

---

AsOf is a temporal fact ledger: a structured, dated, sourced record of what is true and what changed, built for AI retrieval.